ClinicalTrials.gg
RecruitingNCT06434597Updated Aug 17, 2025

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

A Phase 2 interventional study of SPH5030 in Biliary Tract or Colorectal Cancer With Her2-positive/Mutated, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Recruiting at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 603 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
506th of 891
60 · median 80
Started
2024
with 156 others
Phase 2
349 of 1,136
177 open now
Primary completion
2026-12
later than 301 of 602 live
Registered
762nd of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 506th largest by planned enrollment of the 891 interventional ones that give a count, is one of 157 that started in 2024, is one of 349 in phase 2, reaches primary completion later than 301 of the 602 other live ones, and was the 762nd registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.

03

Conditions studied

  • Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. and/or unresectable advanced colorectal adenocarcinoma, or locally advanced, recurrent, metastatic and/or unresectable advanced biliary tract carcinoma
  2. positive or HER2 gene mutation;
  3. Meet the requirements of previous treatment;
  4. performance status of 0 or 1;
  5. Expected survival ≥ 3 months;
  6. No serious abnormalities in hematopoietic function, liver or kidney function;
  7. Females who are not pregnant, non-lactating.. Subjects who complied with the requirements of the protocol.;
  8. Fully informed subjects who voluntarily sign the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have previously received anti- molecular targeted therapy;
  2. Subjects who have been treated with any other clinical trial drug within 4 weeks prior to the first dose;
  3. Subjects with uncontrolled or severe cardiovascular and cerebrovascular diseases; Subjects with severe lung disease; 4. Subjects who may have conditions that affect the absorption, distribution, metabolism, or excretion of the study drug determined by the investigator;

5 Subjects who are taking potent or CYP2C8 inhibitors or inducers; 6 Subjects with other in the past 5 years; 7 Subjects with CNS system with clinical symptoms; 8 Subjects who do not meet the protocol requirements for and C at screening, have a history of immunodeficiency, or other acquired、congenital immunodeficiency diseases, or have a history of organ transplantation; 9. Other situations that do not meet the requirements of the protolol.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SPH5030

    Drug: SPH5030

Interventions

  • SPH5030:Oral, QD, 600mg

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1.

    Time frame: Approximately 2 years

Secondary outcomes

  1. Duration of remission (DOR)

    DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause.

    Time frame: Approximately 2 years

  2. Disease control rate (DCR)

    DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease.

    Time frame: Approximately 2 years

  3. Progression-free survival (PFS)

    From the start date of study treatment to the date of progression disease or death , whichever occurred first.

    Time frame: Approximately 2 years

  4. Overall Survival (OS)

    Determination of the overall survival times of all patients

    Time frame: Approximately 2 years

  5. Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration

    Time frame: Approximately 2 years

07

Study locations

30 of 30 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 29 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2024
First posted
May 30, 2024
StartActual
Jul 17, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06434597
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Jul 17, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 17, 2025

Study contacts

Jianming Xu
Contact
jfjzyygw@163.com
0086-010-66937166

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPH-5030

Start the discussion